$ABBV The company has a strong drug pipeline that will only further strengthen once the acquisition of Allergan is finalized later this year. ABBV has and will continue to be a strong dividend player based on their strong cash flows and low payout ratio

    Get The Stocktwits Daily Rip

    ©2020 StockTwits, Inc. All rights reserved.
    Market Data by Xignite and BATS BZX Real-Time Price

    Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC. ST Invest is a wholly owned subsidiary of StockTwits, Inc.
    Investing in securities products involves risk, including possible loss of principal.
    Please read important legal disclosures.